Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Thermo Fisher Scientific Inc., profitability ratios (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).


The analysis of the quarterly financial metrics reveals significant trends in profitability and efficiency ratios over the observed period.

Gross Profit Margin
The gross profit margin shows a declining trend from 51.47% at the start of the period to a low of approximately 39.75% in the third quarter of 2023. Following this decline, the margin stabilizes and gradually improves to about 41.27% by the end of the last reported quarter. This pattern suggests increasing cost pressures or pricing challenges initially, followed by efforts that have somewhat restored margin levels.
Operating Profit Margin
Operating profit margin also decreases markedly from 27.68% to a low of around 15.42% by mid-2023, indicating erosion in operating efficiency or rising operating expenses relative to sales. However, a gradual recovery trend appears thereafter, with margins increasing to roughly 17.16% by the end of the period. The operating margin follows a similar pattern to the gross margin but shows more volatility, reflecting potential fluctuations in operational costs or restructuring impacts.
Net Profit Margin
The net profit margin declines from 22.08% to about 13.14% over the same timeframe, reaching its lowest point mid-2023 before moderately increasing to around 15.02% by the last quarter. This reduction indicates diminishing profitability after all expenses, highlighting impacts from both cost structures and possibly tax or interest expenses. The slight recovery towards the end suggests improving control over non-operating expenses or tax efficiencies.
Return on Equity (ROE)
ROE decreases from 22.6% down to approximately 12.52% by early 2024 and remains relatively stable with minor fluctuations thereafter, ending near 12.88%. This significant decline indicates reduced profitability against shareholder equity, possibly due to lower net income or increased equity base. The stabilization in later quarters points to a plateau in profitability performance or capital management.
Return on Assets (ROA)
ROA similarly declines from 12.02% to a low near 6.07%, with minor improvements and slight fluctuations afterward, settling around 6.38%. This trend reflects a reduction in asset efficiency to generate net income, possibly due to increased asset base or lower income generation efficiency. The consistency in later periods suggests asset utilization has stabilized at a lower profitability level compared to the beginning of the period.

Overall, the data indicates that profitability margins and returns declined substantially during the initial years, reaching troughs approximately in mid-2023, followed by modest recoveries and stabilization in the subsequent quarters. These patterns could be attributed to external market factors, cost pressures, or internal operational challenges that the company has been addressing with gradual effectiveness. The recovery across margins and returns, while moderate, suggests some success in strategic or operational adjustments leading to improved profitability and efficiency metrics.


Return on Sales


Return on Investment


Gross Profit Margin

Thermo Fisher Scientific Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Selected Financial Data (US$ in millions)
Gross profit
Revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).

1 Q3 2025 Calculation
Gross profit margin = 100 × (Gross profitQ3 2025 + Gross profitQ2 2025 + Gross profitQ1 2025 + Gross profitQ4 2024) ÷ (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data over multiple quarters reveals notable trends in revenue, gross profit, and gross profit margin. An analysis of these metrics provides insights into the company's operational performance and profitability dynamics.

Revenues
Revenues exhibit a general upward trajectory from the beginning of the period through to the latter quarters. Starting at approximately $9.9 billion, revenues increased to a peak exceeding $11.8 billion in early 2022. Following this peak, revenues displayed some fluctuations but largely maintained levels above $10 billion. The later quarters show a pattern of stabilizing revenues around $10.3 to $11.4 billion, indicating a mature revenue base with moderate growth and periodic variation.
Gross Profit
Gross profit values generally follow the trend of revenues, with some variance. Initially, gross profit reached over $5.2 billion but declined in the middle periods, notably dipping to a low near $4.3 billion in late 2022. Despite these fluctuations, the gross profit recovered gradually, reaching above $4.5 billion towards the end of the latest quarters. This pattern suggests periodic challenges impacting cost of goods sold or pricing power, but the company has demonstrated some resilience in restoring gross profit levels.
Gross Profit Margin
The gross profit margin shows a distinct downward trend over the observed periods. Beginning above 51% in early 2021, the margin declined sharply through 2022, bottoming out near 39.75% to 40.28%. Although slight improvements appear in subsequent quarters, the margin remains substantially below the initial levels, stabilizing around 41% in the most recent periods. This sustained reduction in gross profit margin indicates rising cost pressures or changes in product mix that have compressed profitability despite stable or growing revenues.

In summary, the company experienced revenue growth followed by a phase of stabilization, while gross profit exhibited more volatility with a mid-period trough and partial recovery. The declining gross profit margin throughout the timeframe points to potential cost management challenges or pricing pressures impacting profitability. The relative stabilization of margin near 41% in later quarters suggests some mitigation efforts, but overall profitability remains under pressure compared to earlier periods.


Operating Profit Margin

Thermo Fisher Scientific Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Selected Financial Data (US$ in millions)
Operating income
Revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).

1 Q3 2025 Calculation
Operating profit margin = 100 × (Operating incomeQ3 2025 + Operating incomeQ2 2025 + Operating incomeQ1 2025 + Operating incomeQ4 2024) ÷ (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Operating Income

The operating income displays a fluctuating trend over the analyzed quarters. Beginning with a relatively strong figure above 3 billion USD in early 2021, the value dropped significantly in the mid-year quarters of 2021, reaching a low just above 1.5 billion USD in early 2023. Following this period, operating income shows a gradual recovery, with increments through late 2023 and 2024, reaching over 1.9 billion USD by late 2025. Despite this improvement, it does not return to the initial peak levels observed in early 2021.

Revenues

Revenue figures exhibit more stability relative to operating income but present noticeable variability. The revenues peaked near 11.8 billion USD in the second quarter of 2022 but then experienced a decline and a series of fluctuations around the 10 to 11 billion USD range throughout 2023 and 2024. There is a moderate upward trend towards the final periods, with revenue reaching approximately 11.1 billion USD by the end of 2025.

Operating Profit Margin

The operating profit margin declined steadily from approximately 27.7% in early 2021 to about 16% by late 2022 and early 2023. After this decline, margins stabilize between 15.4% and 17.2% through 2023 and 2024, indicating some recovery but remaining well below the initial levels. This suggests that despite fluctuations in revenues and operating income, efficiency or profitability ratios have not fully rebounded to prior highs.

Summary of Financial Trends

The overall analysis reveals that operating income and profit margins have been under pressure since early 2021, with a significant reduction in both metrics by early 2023. Revenues demonstrate more resilience but also fluctuate within a moderate range. The latter part of the observation period indicates some recovery in operating income and margins, alongside a gradual increase in revenue. These movements could reflect operational challenges or changing market conditions impacting profitability and efficiency, despite relatively steady top-line performance.


Net Profit Margin

Thermo Fisher Scientific Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).

1 Q3 2025 Calculation
Net profit margin = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2024) ÷ (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Revenue Trends
The revenue figures exhibit a generally stable pattern with fluctuations over the reported quarters. Starting from approximately $9.9 billion in early 2021, revenues climbed to a peak near $11.8 billion in early 2022, followed by a mild decline and moderate oscillations through 2023 and 2024. Although some quarters show slight dips, the overall revenue level remains within a range of approximately $10.3 billion to $11.4 billion, indicating consistent business activity with moderate seasonal or market influences.
Net Income Attributable to the Company
Net income displays considerable variability across the periods. Initial values around $2.3 billion decreased sharply in mid-2021 before partially recovering late in the year. A second decline is observed during 2022, reaching lows near $1.5 billion, but a rebound occurs towards late 2023 and into 2024, peaking again close to or above $1.8 billion in select quarters. This pattern suggests episodic impacts on profitability, possibly from operational expenses, investment activities, or market conditions affecting earnings.
Net Profit Margin Dynamics
Net profit margins have shown a downward trend from over 22% in early 2021 to levels closer to 15% in recent quarters. This contraction indicates that although revenues have remained relatively stable, the proportion of revenue converted to net income has declined significantly. Margins stabilized somewhat around the 13% to 15% range from 2023 onward, reflecting a new norm of reduced profitability efficiency or increased costs relative to sales.
Integrated Insights
The data reveals that while revenue has maintained a stable trajectory with periodic fluctuations, the company has experienced diminishing net profit margins and a decline in net income magnitude at times. These trends point to potential challenges in cost management, pricing pressures, or increased operating expenses that have impacted profitability more than top-line growth. The partial recovery of net income in later periods suggests adaptive measures or favorable market conditions beginning to take effect, although margins have not returned to earlier high levels.

Return on Equity (ROE)

Thermo Fisher Scientific Inc., ROE calculation (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total Thermo Fisher Scientific Inc. shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).

1 Q3 2025 Calculation
ROE = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2024) ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial indicators reveals several notable trends in the company's profitability and equity position over the periods examined.

Net Income attributable to the company (US$ in millions)
Net income exhibits fluctuations with a generally declining trend from mid-2021 through late 2023. It starts at a high point of 2,337 million USD in April 2021, declines towards a trough of 1,289 million USD by April 2023, and then demonstrates some recovery through the remainder of 2023 and into 2024. Despite this partial rebound, net income does not return to the initial levels observed in early 2021. The values in 2024 and early 2025 stabilize within a range of roughly 1,300 to 1,800 million USD, indicating reduced volatility but also lower earnings compared to the earliest period.
Total Shareholders’ Equity (US$ in millions)
Shareholders’ equity shows a consistent upward trend throughout the entire period. Beginning at approximately 35,058 million USD in April 2021, equity steadily increases quarter over quarter, reaching over 51,000 million USD by the end of the most recent quarter in September 2025. This growth indicates strengthening of the company's capital base, potentially reflecting retained earnings, capital issuance, or appreciation in asset values. The steady rise in equity occurs despite the volatility and partial decline observed in net income.
Return on Equity (ROE, %)
ROE declines notably over the period examined. In early 2021, ROE is robust at approximately 22.6%, but subsequently decreases each quarter, dropping below 15% during 2023 and stabilizing around 12.5%-13.5% in 2024 and 2025. This declining trend suggests that despite increasing shareholders’ equity, the company’s ability to generate profits relative to equity is diminishing. The decrease in ROE corresponds with the observed reductions in net income, indicating less efficient utilization of equity capital over time.

In summary, the company's financial data exhibits a continuous increase in shareholders’ equity alongside a decline in net income and ROE. This combination implies that while the company's capital base is growing, its profitability and efficiency in leveraging that equity for income generation are weakening. The data may point to challenges in operational performance or market conditions that are impacting earnings, despite a solid equity foundation.


Return on Assets (ROA)

Thermo Fisher Scientific Inc., ROA calculation (quarterly data)

Microsoft Excel
Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).

1 Q3 2025 Calculation
ROA = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2024) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


Net Income Trend
The company's net income attributable showed notable fluctuations over the reported periods. Initial quarters reflected strong performance, peaking early with values above 2,000 million USD. Subsequently, a downward trend was observed through most quarters of 2022 and early 2023, reaching lows around 1,289 million USD. However, from mid-2023 onwards, a recovery phase is evident, with net income gradually increasing again toward the end of the most recent periods, stabilizing near 1,600 to 1,800 million USD.
Total Assets Movement
Total assets displayed an overall increasing trend with some volatility. Starting at approximately 65,931 million USD, assets grew steadily, crossing the 95,000 million USD mark by late 2021. This level fluctuated mildly in subsequent quarters but generally trended upward, reaching over 103,000 million USD by the end of the latest reporting period. This indicates continued asset accumulation or investment by the company through the sample timeline.
Return on Assets (ROA) Development
The return on assets percentage reveals a declining trend from early high levels above 12% to a lower range around 6% in recent quarters. The initial periods show strong asset efficiency, which diminishes sharply by late 2021 and remains relatively stable but weaker from 2022 forward. There is slight variability but the ROA remains consistently around 6% in the most recent intervals, suggesting that although assets increased, net income growth did not proportionally follow, affecting overall asset profitability.
Overall Analysis
The financial data indicates a period of robust profitability early on, followed by reductions in net income and asset returns while the total asset base expanded significantly. This pattern may suggest strategic investments or acquisitions that have increased asset size but temporarily pressured profitability ratios. The recent signs of net income recovery alongside maintaining asset growth could reflect an improving operational performance or enhanced asset utilization moving forward. Continuous monitoring of net income relative to asset growth will be vital to assess whether the company can improve its returns on assets in the future.